Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY20 results · Oct–Dec 2019
Solara Active Pharma Sciences reported revenue from operations of ₹343.68 crore (down 3.5% from Q3 FY19) and net profit of ₹41.33 crore (up 87.0% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 343.68 | 356.23 | −3.5% | 351.13 | −2.1% |
| Other income | 6.08 | 3.88 | +56.7% | 4.95 | +22.8% |
| Total income | 349.76 | 360.11 | −2.9% | 356.08 | −1.8% |
| Profit before tax | 41.33 | 22.10 | +87.0% | 29.18 | +41.6% |
| Net profit for the period | 41.33 | 22.10 | +87.0% | 28.88 | +43.1% |
| Attributable to shareholders of the company | 41.32 | 22.09 | +87.1% | — | — |
| EPS, basic (₹) | 16.00 | 8.96 | not comparable | 11.21 | +42.7% |
| Net margin (%) | 12.0 | 6.2 | 8.2 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 343.68 | 347.94 | −1.2% | 350.36 | −1.9% |
| Other income | 6.10 | 2.52 | +142.1% | 4.41 | +38.3% |
| Total income | 349.78 | 350.46 | −0.2% | 354.77 | −1.4% |
| Profit before tax | 41.21 | 24.39 | +69.0% | 36.79 | +12.0% |
| Net profit for the period | 41.21 | 24.39 | +69.0% | 36.79 | +12.0% |
| EPS, basic (₹) | 15.95 | 9.89 | not comparable | 14.27 | +11.8% |
| Net margin (%) | 12.0 | 7.0 | 10.5 |
Consolidated
- Filed with BSE
- 06 Feb 2020, 14:04 IST
- Board meeting
- 06 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2020, 14:04 IST
- Board meeting
- 06 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE